Related Experiment Video

Updated: Jun 26, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Anlotinib-containing regimens in HR+ advanced breast cancer after prior CDK4/6 inhibitor progression

Yifei Chen1, Binliang Liu2, Zhanhong Chen3

  • 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China.

NPJ Breast Cancer
|June 24, 2026
PubMed

Insights

Anlotinib-containing regimens show potential in HR+/HER2- advanced breast cancer patients post-CDK4/6 inhibitor therapy. Progression-free survival was 6.4 months, with notable response rates and manageable safety.

Area of Science:

  • Oncology
  • Clinical Pharmacology

Background:

  • Hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer often progresses after CDK4/6 inhibitor therapy.
  • Identifying effective subsequent treatments for this patient population is crucial.

Purpose of the Study:

  • To evaluate the efficacy and safety of anlotinib-containing regimens in HR+/HER2- advanced breast cancer patients who have progressed on prior CDK4/6 inhibitor therapy.
  • To identify predictors of progression-free survival (PFS) in this setting.

Main Methods:

  • Retrospective study including 80 patients with HR+/HER2- advanced breast cancer.
  • Patients received anlotinib-containing regimens after progression on CDK4/6 inhibitors.
  • Analysis of progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events.

Main Results:

  • Median PFS was 6.4 months. Objective response rate (ORR) was 30.0%, and disease control rate (DCR) was 87.1%.
  • Age ≥ 60 years and bone metastasis were poor PFS predictors; prior CDK4/6 inhibitor treatment for ≥ 6 months was a favorable predictor.
  • Grade 3-4 adverse events occurred in 12.5% of patients, primarily neutropenia and elevated aspartate aminotransferase.

Conclusions:

  • Anlotinib-containing regimens demonstrate potential clinical activity in HR+/HER2- advanced breast cancer patients progressing after CDK4/6 inhibitors.
  • Further prospective evaluation is warranted due to the retrospective nature and potential confounders.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...